North Staffordshire Joint Formulary Formulary


	North Staffordshire Joint Formulary North Staffordshire Clinical Commissioning Group Stoke-on-Trent Clinical Commissioning Group

Search

Formulary Chapter 11: Eye - Full Chapter

11.08.02

Ocular diagnostic and peri-operative preparations and photodynamic treatment

11.08.02

Ocular diagnostic preparations

11.08.02

Ocular peri-operative drugs

Apraclonidine (Iopidine^®)

Formulary

Apraclonidine 5mg/ml eye drops
Apraclonidine 1% eye drops (0.25ml unit dose)

Used to control or prevent post surgical elevations in intraocular pressure that occur in patients after anterior segment laser surgery.

Ketorolac trometamol
(Acular^®)

Formulary

Ketorolac trometamol 0.5% eye drops

Nepafenac (Nevanac^®)

Formulary

Nepafenac 1mg/ml eye drops
Nepafenac 3mg/ml eye drops

Restriction: Reduction of postoperative macular oedema associated with cataract surgery in diabetic patients, previous uveitis, vein occlusions and complicated surgery

Povidone iodine (Minims^®)

Formulary

Minims Povidone iodine 5% eye drops (0.4ml unit dose)

11.08.02

Subfoveal choroidal neovascularisation

11.08.02

Vitreomacular traction

....

Key

	Notes
	Section Title (top level)
	Section Title (sub level)
	First Choice item
	Non Formulary section
	Restricted Drug
	Unlicensed
	Display tracking information
	Link to adult BNF
	Link to children's BNF
	Link to SPCs
	Scottish Medicines Consortium

	Cytotoxic Drug
	Controlled Drug
	High Cost Medicine
	Cancer Drugs Fund
	NHS England
	Homecare
	CCG
	High Cost Drug Approval System

Traffic Light Status Information

Status	Description
	Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available
	Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.
	Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary
	Medicines which can be prescribed in either Primary or Secondary Care.
	These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.